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AbstrACt
Objectives To investigate whether cervical screening 
attendance differs between human papillomavirus (HPV)-
vaccinated and unvaccinated women and to investigate 
potential underlying socioeconomic factors.
Design Prospective cohort using registry linkage of 
vaccinations, screening invitations, screening attendance 
and socioeconomic covariates.
setting Swedish national HPV vaccination and cervical 
screening programmes.
Participants All Swedish women born between 1988 and 
1991 and invited to screening (n=261 434).
Outcome measures All participants were followed for up 
to 3 years. Screening attendance was compared between 
HPV-vaccinated and unvaccinated women. HR and 95% CI 
were estimated using Cox regression.
results Vaccination age averaged 18.1 years and the 
coverage for≥1 dose was 13.5%. In HPV-vaccinated 
women (n=35 460), screening attendance was higher 
than in unvaccinated women (n=225 974) (74%vs69%, 
p<0.001). The crude HR of attendance in HPV-vaccinated 
women was 1.32 (95% CI 1.30 to 1.34). A positive 
association remained after adjustment for education, 
income and migration history (HR=1.10, 95% CI 1.09 to 
1.12).
Conclusion HPV-vaccinated women were more likely 
to attend screening than unvaccinated women. Yet, the 
question needs to be reassessed in routinely vaccinated 
cohorts, since the vaccinated women included here 
represent a selected group and may be prone to more 
health-conscious habits.
IntrODuCtIOn
Human papillomavirus (HPV) vaccines do 
not provide complete protection against 
all oncogenic HPV types; hence, cervical 
screening remains essential in HPV-vacci-
nated women.1 2 Sweden approved the quad-
rivalent HPV vaccine in October 2006 and 
organised vaccination programmes began in 
June 2012. In the interim period, a smaller 
proportion of Swedish girls aged 13–17 years 
were vaccinated opportunistically, that is, in a 
non-organised manner. The cost of approxi-
mately €330 for three doses was partially or 
wholly subsidised, depending on the family’s 
medical expense level, as part of a national 
pharmaceutical benefits scheme. On average, 
the cost for three doses of the vaccine was 
reduced to around half by this scheme.3 4 The 
subsidy was later extended to women up to 
the age of 26. These girls and young women 
were however vaccinated later than at the 
recommended age of 10–12 years,5 meaning 
that many had likely already been exposed 
to oncogenic HPV types.6 Given the vaccine’s 
inability to cure ongoing infections,7 the 
potentially weaker vaccine-induced antibody 
response in 16–23-year-olds compared with 
younger girls8 and the decrease in effective-
ness with increasing age at vaccination,9 10 
continued cervical screening is crucial espe-
cially in these women. In Sweden, invita-
tions to cervical screening are issued every 
3 years for women aged 23–50, every 5 years 
for women aged 51–64 and to every woman 
migrating to Sweden.11 12 Eighty-two per cent 
of Swedish women attend at least one cervical 
screening within the recommended time 
interval.11 Women who did not attend are 
reinvited after 1 year.11 
strengths and limitations of this study
 ► This study used register data with very high com-
pleteness and individual linkage to socioeconomic 
covariates. The overall level of differential misclas-
sification and bias in this study is minimal and the 
internal validity is high.
 ► This means the generalisability to current vaccinat-
ed cohorts is excellent.
 ► Our chief limitation is that the participants still were 
not part of an organised school-based programme, 
and thus self-selected (on their own and/or parental 
volition) whether to be vaccinated or not.
 ► The latter limitation entails that generalisability to 
future vaccinated cohorts is uncertain—further fol-
low-up is needed of these.
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Some concerns about decreasing screening attendance 
were voiced on the HPV vaccine’s introduction, supposing 
that vaccinated women might perceive a false sense of 
full protection and therefore refrain from screening.13–15 
However, only one study has so far reported decreased 
screening attendance in HPV-vaccinated women,16 several 
others suggest that vaccinated women screen equally or 
more often than unvaccinated women.17–24
This was also found in a Swedish study on birth cohorts 
1977–1987.18 In that study, vaccinations occurred entirely 
at an out-of-pocket price of €330 with a strong self-se-
lection of women.18 Moreover, vaccine uptake was only 
0.8% in the assessed birth cohorts,18 resulting in limited 
generalisability of findings. The present study aims to 
reassess the association between HPV vaccination and 
cervical screening in the birth cohorts 1988–1991, who 
were younger at vaccination and had higher vaccination 
uptake levels of up to 29%,5 as part of our continuous 
follow-up of HPV vaccination in Sweden.
MethODs
study population
In this national register-based cohort study, the study 
population included all women registered in Sweden 
who were born between 1988 and 1991, and were invited 
to cervical screening (figure 1). Women who emigrated 
or died prior to the study period or who did not receive 
a screening invitation were excluded. The non-invited 
women were subject to a separate descriptive analysis. 
Moreover, women were excluded if they had screened 
on their own initiative before being invited. The genetic 
component in cervical cancer may influence the sensi-
tivity to persistent HPV infections25 and it is possible that 
more early screeners, for example, had a family history 
of cervical pathology. They may also have been more 
likely to have symptoms of bleeding and/or condyloma, 
which would render them unrepresentative of the main 
study population. Early screeners, that is, those screening 
before invitation, were therefore also subject to a separate 
descriptive analysis.
Cohort entry was defined as date of the first screening 
invitation after 1 January 2010, that is, when the first 
women in the study turned 22–23 and thus were eligible 
to start organised screening. Women were followed 
until attending screening, or until censored at emigra-
tion, death, 3 years after invitation (ie, one screening 
interval) or the end of the study period on 31 December 
2015, whichever occurred first.
Figure 1 Composition of the register-derived study cohort. 
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Data sources and definition of variables
Initially, records of all women born in 1988–1991 were 
extracted from Sweden’s Total Population Register. Indi-
vidual-level data from other population-based registers 
were then cross-linked based on unique personal iden-
tification numbers and pseudonymised before analysis. 
Dates of death and migration were retrieved from the 
Causes of Death Register and the Migration Register, 
respectively.
Dates of screening invitations, that is, the point of study 
entry, and all organised and opportunistic smears, that is, the 
outcome events, were retrieved from the Swedish National 
Cervical Screening Registry (NKCx as Swedish acronym), 
which is 100% complete since 1995.11 HPV vaccination was 
defined as receipt of at least one dose of the bivalent or 
quadrivalent HPV vaccine before study entry (A one dose-
only vaccine regimen is not currently recommended, yet 
for this study, we hypothesised that one dose might already 
suffice to be associated with differing screening uptake, 
whether positive or negative). Women who were vaccinated 
after study entry were censored. An additional sensitivity 
analysis instead treated HPV vaccination as a time-varying 
exposure. Vaccination data originated from the SVEVAC 
register, which covers 85%–90% of vaccines administered 
in Sweden5 and from the Prescribed Drug Register (PDR), 
which captures all medical prescriptions and is complete 
since 2005.26 Participants were considered to have bene-
fitted from the subsidy when their first vaccination occurred 
after 9 May 2007 for women then aged 13–17 and after 28 
June 2012 for women up to age 26.4
The Database for Health Insurance and Labour 
Market Studies (LISA as Swedish acronym)27 provided 
data on education level at study entry of individuals 
and their biological or adoptive parents. Linkage to 
parents’ records was performed using the Multi-Gener-
ation Register (MGR). Education was categorised into 
compulsory school (≤9 years), high school (9–12 years) 
and university and above (≥12 years). LISA also provided 
data on disposable income, measured at study entry in 
Swedish kronor (SEK) per year. The quartile cut-offs were 
93 100, 136 900 and 183 500 SEK for individual income 
and 128 000, 193 700 and 387 800 SEK for family income. 
Family history of abnormal cytological screening results 
and histological-confirmed CIN2+ lesions was obtained 
for all first-degree female relatives from the NKCx, as 
linked via MGR.
statistical analysis
We compared the cumulative incidence proportion of 
screening attendance after invitation between HPV-vacci-
nated and unvaccinated women, using Kaplan-Meier func-
tion. HR with 95% CI of screening attendance among the 
HPV-vaccinated compared with the unvaccinated were 
estimated using Cox regression, using attained age as the 
underlying time scale, as previously described.18
Using explorative model building, potential 
confounding factors were added to the crude model. 
Only covariates that noticeably affected the main HR 
estimate by at least one decimal place and improved 
model fit were retained in the main effects model (indi-
vidual education, individual income, migration history); 
others were dropped (family income, parents’ education, 
family history of cervical lesions). For the fully adjusted 
model, see online supplementary 1. Interaction effects 
were explored between vaccination and education based 
on previous research18 28 and also between vaccination 
and income and vaccination and migration history, since 
the high vaccine cost might have led to differential effects 
depending on income quartile or migration status. Strat-
ified analyses were performed to explore the association 
by vaccine dose number. The Akaike information crite-
rion was used to determine the best-fitting model. All 
tests of significance were two-sided and p value of 0.05 
was considered statistically significant. No violations of 
the proportional hazards assumption were detected when 
visually inspecting scaled Schoenfeld residuals.29
sensitivity analyses
To investigate if our results were robust, vaccination 
status was first redefined as having received the full three 
vaccine doses. Second, only women invited to screening 
at ages 22–24 were included, as the women who received 
invitations at older ages might differ in characteristics, 
for instance, in migration history. Third, vaccination was 
redefined as a time-varying exposure.
Data linkage and management was performed with SAS 
V9.4 software (SAS Institute, Cary, North Carolina, USA). 
Statistical analyses were conducted in Stata V.14 software 
(Stata Corp, Texas, USA).
Patient involvement
No patients were involved in setting the research ques-
tion or the outcome measures, nor were they involved 
in developing plans for design or implementation of the 
study. No patient was asked to advise on interpretation or 
writing up of results. There are no plans to disseminate 
the results of the research to study participants or the 
relevant patient community.
results
Characteristics of the study population
The final cohort comprised 261 434 women (figure 1): 
13.6% (n=35 460) were HPV-vaccinated with at least one 
dose and most had received all three doses. HPV-vacci-
nated women were more likely to have university educa-
tion, to be in the upper income quartile and to be born 
in Sweden (table 1).
Vaccination coverage increased by birth year, with 3.6% 
among women born in 1988, 6.7% in those born in 1989, 
15.3% in those born in 1990 and 28.6% in those born in 
1991. Vaccinations occurred at a mean age of 18.1 years 
(SD=1.9 years) and 75.1% of vaccinations were eligible for 
the subsidy (see online supplementary 2).
The descriptive analysis on the excluded women 
showed that those who had screened on their own 
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initiative before being invited (n=10 838) had a higher 
vaccination coverage at 22.4%. A family history of cervical 
lesions was present in 30.8% of this group, compared with 
23.2% in the main cohort. The overall proportion of early 
screeners (3.7%) was similar to that among the preceding 
10 birth cohorts (3.6%).18 Of those who had not been 
invited to screening (n=3765), 57% were recent immi-
grants and might therefore not have been invited yet. 
Overall, the lack of invitation remained unexplained for 
1637 women. Over half of these also lacked basic demo-
graphic data such as birth country and might therefore 
not have been invited.
screening invitations and attendance
Age at screening invitation was similar in vaccinated 
and unvaccinated women (table 1). A minority of 
women (5.6%) were invited above age 24 and more 
than half of these had a history of migration. The 
crude screening attendance, defined as the proportion 
of being screened up to 3 years after invitation, among 
all women was 70.2%. When stratified by vaccination 
status, this attendance was higher in the vaccinated, 
at 74.4%, compared with the unvaccinated, at 69.6% 
(p<0.001). This pattern emerged early on, remained 
stable throughout follow-up and was statistically signif-
icant (log-rank test p<0.001) (figure 2).
Table 2 displays the crude and adjusted HR for 
screening attendance in vaccinated compared with 
unvaccinated women. In the crude model, vaccinated 
women were 32% more likely to attend screening. The 
difference decreased to 10% in the adjusted model, but 
remained statistically significant. When separating the 
vaccinated group by women’s eligibility for the subsidy, 
results remained similar but with higher attendance 
among women who paid the full vaccine cost themselves 
(see online supplementary 3).
The analysis by vaccine dose yielded a distribu-
tion of 7.6% for one dose, 10.9% for two doses and 
81.5% for three doses among vaccinated women (p for 
trend <0.001). Compared with unvaccinated women, 
the association between vaccination and screening was 
positive in all strata and the overall difference in atten-
dance was largest in the three-dose stratum (table 2). 
Table 1 Characteristics of the study cohort of women born 1988–1991
Unvaccinated Vaccinated Total
n (%) n (%) n (%)
Total cohort 225 974 (100.0) 35 460 (100.0) 261 434
Age at screening invitation (years) 23.3 (SD 0.8) 23.2 (SD 0.6) 23.3 (SD 0.8)
Follow-up time (person-years) 
  Total follow-up time 230 945 25 371 256 316 
  Mean follow-up time 1.02 (SD 1.03) 0.72 (SD 0.79) 0.98 (SD 1.01) 
Screening attendance
  Attended screening 157 287 (69.6) 26 368 (74.4) 183 655 (70.2)
  Did not attend screening 68 687 (30.4) 9 092 (25.6) 77 779 (29.8)
Education
  Compulsory school (<9 years) 20 927 (9.3) 1 049 (3.0) 21 976 (8.4)
  High school (9–12 years) 100 090 (44.3) 12 933 (36.5) 113 023 (43.2)
  University (>12 years) 81 049 (35.9) 21 191 (59.8) 102 240 (39.1)
  Missing 23 908 (10.6) 287 (0.8) 24 195 (9.3)
Individual income
  Quartile 1 59 570 (26.4) 4 563 (12.9) 64 133 (24.5)
  Quartile 2 56 027 (24.8) 8 101 (22.9) 64 128 (24.5)
  Quartile 3 54 052 (23.9) 10 077 (28.4) 64 129 (24.5)
  Quartile 4 51 380 (22.7) 12 716 (35.9) 64 096 (24.5)
  Missing 4 945 (2.2) 3 (0.0) 4 948 (1.9)
Migration history
  Born in Sweden 178 847 (79.1) 33 924 (95.7) 212 771 (81.4)
  Immigrated ≥10 years ago 14 251 (6.3) 1 175 (3.3) 15 426 (5.9)
  Immigrated <10 years ago 32 876 (14.6) 361 (1.0) 33 237 (12.7)
All differences between exposure groups, as assessed with t-tests and χ2 tests, were statistically significant at p<0.001, as expected given 
the large sample size.
Vaccinated, human papillomavirus vaccinated with ≥1 dose; SD, standard deviation.
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All three tested interactions (table 3) were statistically 
significant (likelihood ratio test p<0.001 for each) and 
separate inclusion of each interaction term improved 
model fit. Attendance differed most noticeably 
between vaccinated and unvaccinated women in the 
lowest income quartile, at 22%, and least in the highest 
quartile, at 3%. Similarly, the association was stronger 
in women who had immigrated to Sweden than in 
those born there. Regarding education, the association 
in women with university education is slightly higher 
than that in women in the other categories (table 3).
sensitivity analyses
When redefining subjects as vaccinated after only the 
full three doses, vaccination uptake was only 11.1%, 
but results remained unchanged. Results also remained 
unchanged when excluding the 5.6% of women who were 
invited after age 24, and when redefining vaccination as a 
time-varying exposure (see online supplementary 4).
DIsCussIOn
Young HPV-vaccinated women, most of which were vacci-
nated under a national benefits scheme, were 32% more 
likely to attend cervical screening than unvaccinated 
women. The difference decreased to 10% after adjusting 
for education, income and migration history, suggesting 
that the crude association is at least partially driven by 
socioeconomic factors. This is similar to our previous 
evaluation of attendance in adult HPV-vaccinated women 
in the same screening programme.18
This finding does not support the notion that HPV-vac-
cinated women might discontinue screening. Any discus-
sion of causal factors behind the observed association 
must however be cautious due to the observational design. 
One possible explanation is that vaccination acts as an 
educational opportunity; raising awareness about cervical 
cancer and increasing women’s propensity to screen. 
In this cohort, HPV awareness was further amplified by 
radio, television and letter campaigns targeted at female 
teenagers, which started in June 20073 and perhaps most 
strongly resonated with vaccinated women. Another possi-
bility is that positive attitude to preventive health services 
clusters in women who are both vaccinated and attend 
screening. The overproportionate vaccine uptake among 
women who initiated screening before being invited also 
hints in this direction. The clustering of HPV-related and 
screening-related health behaviours is a known phenom-
enon,24 30 implying that the disparity in cervical cancer 
prevention efforts between the ‘worried well’31 and the 
unvaccinated non-attenders may be widening also in 
Sweden.
Our interaction analyses should provide insight into 
the interplay between the HPV vaccination and socioeco-
nomic factors. The association between vaccination and 
screening was weakest in wealthy and in Swedish-born 
women and strongest in low-income and in immigrant 
women. It should however be noted that vaccine uptake 
in immigrated women was comparatively low at 1%–8% 
(data not shown), hence strong self-selection may well 
have been present. Overall, being vaccinated seems to 
only be associated with a small attendance increment 
among wealthier Swedish-born women, while larger 
increments were observed in low-income groups and 
those with a migration background.
The findings of this study contribute to a growing body 
of evidence that the HPV vaccination is not associated 
with reduced cervical screening uptake. With one excep-
tion, numerous empirical studies on vaccinated women’s 
screening participation showed consistent results across 
Figure 2 Cumulative incidence proportion of cervical 
screening attendance after invitation in women born 1988–
1991, by human papillomavirus vaccination status.
Table 2 Crude model, adjusted model with main effects, 
and model with the exposure split to three levels on the 







(%) HR (95% CI)
Crude model
Unvac. 157 287 (69.6) ref.
Vac. 26 368 (74.4) 1.32 (1.30 to 1.34)
Adjusted model with main effects*
Unvac. 157 287 (69.6) ref.
Vac. 26 368 (74.4) 1.10 (1.09 to 1.12)
Exposure split by number of doses*†
  Unvac. Zero doses 157 287 (69.6) ref.
  Vac. One dose 1937 (72.2) 1.05 (1.0 to 1.10)
Two doses 2883 (74.4) 1.08 (1.04 to 1.12)
Three 
doses
21 548 (74.6) 1.11 (1.10 to 1.13)
*HR adjusted for education, income and migration history.
†Exposure level of vaccine dose is defined at study entry, as 
opposed to being a time-varying exposure.
HPV, human papillomavirus; Unvac, unvaccinated; 
Vac., HPV vaccinated with ≥1 dose. 
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varied national and social contexts. Register-based Welsh 
and Scottish studies on catch-up vaccinated cohorts with 
higher HPV vaccination uptake levels than this study 
(49% and 36%) and lower overall screening attendance 
(46% and 47%) also reported higher attendance among 
the vaccinated.19 20 Four American studies report similar 
findings, studying the general population,32 members of 
an integrated healthcare setting24 and women in a safety 
net health system,21 23 respectively. In contrast, an Austra-
lian study reported a 10% lowered attendance among 
HPV-vaccinated women,16 which might in part have been 
due to context-specific factors or a differential overesti-
mation of non-attendance due to data mismatching.16 
Mismatching would not have occurred in the current 
study due to the individual data linkage.
This study’s results closely mirror a Swedish study on 
the preceding 10 birth cohorts 1977–1987 with 0.8% 
vaccine uptake.18 The cumulative incidence propor-
tion of screening over 3 years’ follow-up time was 
similar between the preceding 10 cohorts and the study 
cohorts: 86% of vaccinated and 75% of unvaccinated 
women screened in the preceding cohorts, compared 
with a respective 85% and 75% in the present cohorts. 
It suggests that the positive association between vacci-
nation and screening is robust, even if vaccine uptake 
levels increase.
A positive association with screening attendance 
increased with vaccine dosage number in some 
studies,20 24 while the opposite pattern was found in an 
American study.23 The present study observed a trend 
towards higher attendance with more doses, yet CI over-
lapped. As dose was determined at study entry, some 
women may have received further doses during follow-up, 
which were not counted. While the absolute differences 
Table 3 Interaction models on the association between HPV vaccination and cervical screening attendance (n=261 434)
Model Exposure status Crude attendance n (%) HR (95% CI)
Interaction model 1: vaccination and education*
  Compulsory school 
(<9 years)
Unvac. 12 799 (61.2) ref.
Vac. 612 (58.3) 1.06 (0.98 to 1.15)
  High school (9–12 years) Unvac. 74 178 (74.1) ref.
Vac. 9219 (71.3) 1.07 (1.04 to 1.09)
  University (>12 years) Unvac. 60 390 (74.3) ref.
Vac. 16 228 (77.3) 1.13 (1.11 to 1.15)
  Missing Unvac. 10 116 (42.3) ref.
Vac. 147 (51.2) 1.13 (0.96 to 1.33)
Interaction model 2: vaccination and income†
  Quartile 1 Unvac. 34 748 (58.3) ref.
Vac. 3178 (69.6) 1.22 (1.18 to 1.27)
  Quartile 2 Unvac. 39 866 (71.2) ref.
Vac. 6012 (74.2) 1.17 (1.14 to 1.20)
  Quartile 3 Unvac. 41 505 (76.8) ref.
Vac. 7662 (76.0) 1.10 (1.08 to 1.13)
  Quartile 4 Unvac. 39 874 (77.6) ref.
Vac. 9514 (74.8) 1.03 (1.00 to 1.05)
  Missing Unvac. 1294 (26.2) ref.
Vac. 2 (66.7) 2.96 (0.74 to 11.86)
Interaction model 3: vaccination and migration history‡
  Born in Sweden Unvac. 134 936 (75.5) ref.
Vac. 25 401 (74.9) 1.09 (1.08 to 1.11)
  Immigrated ≥10 years ago Unvac. 7950 (55.8) ref.
Vac. 774 (65.9) 1.52 (1.41 to 1.64)
  Immigrated <10 years ago Unvac. 14 401 (43.8) ref.
Vac. 193 (53.5) 1.29 (1.12 to 1.48)
*HR adjusted for income, migration history and an interaction term between vaccination and education.
†HR adjusted for education, migration history and an interaction term between vaccination and income.
‡HR adjusted for income, education and an interaction term between vaccination and migration history.
HPV, human papillomavirus; Unvac, unvaccinated; Vac., HPV vaccinated with≥1 dose. 
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between doses should thus be interpreted cautiously, the 
trend appears consistent with most previous studies.21 23 24
This national cohort study has its major strength in 
data completeness and the individual linkage to socio-
economic covariates. All registered women from birth 
years 1988–1991 were followed for the entire study period 
with minimal attrition. Data on invitations and screening 
events were complete. Confounding and interactions 
were treated in detail given the individual data linkage. 
A further strength is the prospective objective data collec-
tion, which eliminates the possibility of recall bias. Hence, 
the overall level of differential misclassification and bias 
in this study should be minimal and the internal validity 
should be high.
The main limitation of this observational study is that 
the participants still were not part of an organised school-
based programme, and thus self-selected (on their own 
and/or parental volition) whether to be vaccinated or 
not. Despite excluding the most highly self-selected 
subgroup who screened early on their own initiative, 
socioeconomic selection mechanisms likely determined 
the choice to be vaccinated given the vaccine’s substantial 
cost. This limitation was addressed by adjusting for socio-
economic factors, yet some residual confounding could 
remain and selection bias is likely still present.
A second limitation is the 85%–90% completeness of 
the SVEVAC vaccination register compared with number 
of sold doses in the nation,5 due to which some vaccina-
tions were missed even after complementing with PDR 
data. Moreover, vaccinated immigrant women or native 
Swedes who may have vaccinated abroad would have been 
misclassified as unvaccinated. Yet, given that vaccinated 
women were more likely to attend screening, erroneously 
classifying them as unvaccinated would, if anything, have 
biased results towards the null hypothesis by reducing 
between-group differences. The observed association 
between vaccination and screening should thus not be 
overestimated due to such misclassification.
Future research needs to be repeated in routinely 
HPV-immunised women such as the Swedish birth cohorts 
1993–1998. These women were offered free catch-up 
vaccinations at ages 13–18 and reached 60%–80% vaccine 
uptake; girls born in 1999 and later were offered free 
school-based vaccinations at ages 10–12 and reached 
85% uptake.5 These younger girls will be affected by less 
HPV-related diseases and lower perceived infection risk 
due to the vaccination,9 17 which may alter the association 
between vaccination and screening.
The implications of this study are twofold. First, 
there is currently no apparent need for targeted 
education campaigns to the HPV-vaccinated women 
under study, as they have an equal or higher cervical 
screening uptake. Second, the advent of HPV vacci-
nation seems to widen the disparity between the risk 
groups for cervical lesions and cancer. Women who are 
neither vaccinated nor attend screening regularly face 
a double vulnerability.24 31 33 A similarly stronger asso-
ciation between vaccination and screening attendance 
among the more deprived has also been observed in 
Scotland, where register-based studies similar to this 
are also readily feasible.20 These findings imply an 
even greater disparity of cervical cancer risk among 
deprived girls and young women that warrants partic-
ular concern and intervention. Continuous moni-
toring of attendance rates in later birth cohorts 
eligible for free-of-charge school-based vaccination, 
which achieved higher vaccine uptake and lower socio-
economic disparity,34 will be key to inform this ongoing 
issue. Future prevention efforts should consider how 
to better reach this subgroup.
COnClusIOns
This nationwide study found that HPV vaccination is asso-
ciated with higher cervical screening attendance among 
Swedish girls and women born in 1988–1991. Future 
studies should continue to assess the association between 
HPV vaccination and screening in younger, routinely 
vaccinated cohorts.
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